A double-blind, placebo controlled comparison of two fixed doses of oxytocin and placebo administered intranasally in schizophrenia patients

HS 2011-8256
Schizophrenia, Psychiatry
Steven G. Potkin, MD
The purpose of this research study is to measure the effects of Oxytocin improving symptoms in schizophrenia. Oxytocin is an approved medication by the Food and Drug Administration (FDA) but has not been approved for this indication in schizophrenia.
To be eligible, participants must:
  • Be 18 to 65 years of age
  • Be diagnosed with schizophrenia
  • Be able to provide written informed consent
Participation in the study consists of 8 visits over 8 weeks.
You will not directly benefit from participation in this study. You may benefit from the formal diagnostic procedures, required assessments, and increased scrutiny during the study, which are more rigorous than the community standard for diagnosis and assessment. A more general benefit of this study will be a greater understanding of the benefits of intranasal oxytocin augmentation.
Total payment for participation in this study is up to $450.
Richard Jones, Department of Psychiatry and Human Behavior